New pain drug could make eye surgery recovery safer and faster

NCT ID NCT07269106

Recruiting now Symptom relief Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new painkiller called Anrikefon in 204 adults having eye surgery under general anesthesia. Researchers want to see if it controls pain as well as the standard drug nalbuphine, but with fewer side effects like drowsiness. Participants get one dose during surgery and are monitored for pain, side effects, and recovery speed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anrikefon
What this could lead to: If it works, this could offer a safer painkiller for eye surgery with fewer side effects like dizziness or sedation.
What could go wrong: This is a mid-stage trial with only 204 people, so results may not apply to everyone. The drug might not work as well as expected or could still cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPHTHALMIC SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPHTHALMIC SURGERY OPIOID ANALGESIA POSTOPERATIVE PAIN MANAGEMENT

Contacts and locations

Locations

Eye & ENT Hospital of Fudan University
NOT_YET_RECRUITING

Shanghai, 200031, China
The Affiliated Hospital of Yunnan University
NOT_YET_RECRUITING

Kunming, Yunnan, 650000, China
Zhongshan Ophthalmic Center, Sun Yat-Sen University
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.